Authorized purpose: syngo.via molecular-imaging workflows provide viewing, manipulation, quantification, analysis, and comparison of medical images from one or more modalities and time points, including PET or nuclear-medicine functional data and CT or MR anatomical data. The workflows support disease-management activities in oncology, cardiology, neurology, and organ function, and the images or results may aid radiotherapy treatment planning. The submission also describes Scenium neurology review and syngo MBF quantitative myocardial-blood-flow review for supported PET studies.
Clinical role
Nuclear-medicine image acquisition support, reconstruction, display, quantification, analysis, or comparison under professional review.
Images and patients
PET/SPECT/Nuclear Medicine · Whole-body, cardiac, neurologic, oncologic, organ-function, and radiotherapy-planning anatomy represented in PET, nuclear-medicine, CT, and MR studies
Key limitation
Keep in mind: Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: syngo.via molecular-imaging workflows provide viewing, manipulation, quantification, analysis, and comparison of medical images from one or more modalities and time points, including PET or nuclear-medicine functional data and CT or MR anatomical data. The workflows support disease-management activities in oncology, cardiology, neurology, and organ function, and the images or results may aid radiotherapy treatment planning. The submission also describes Scenium neurology review and syngo MBF quantitative myocardial-blood-flow review for supported PET studies.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole-body, cardiac, neurologic, oncologic, organ-function, and radiotherapy-planning anatomy represented in PET, nuclear-medicine, CT, and MR studies Input: Supported PET, SPECT, nuclear-medicine, CT, MR, tracer, physiologic-signal, and study inputs described in the labeling.
Who uses it?Intended users: Qualified radiologists, nuclear-medicine physicians, and trained imaging professionals.
What does the software produce?Output: Processed, fused, quantitative, comparative, and report-ready molecular-imaging views for professional review.
What is its most important limitation?Key limitation: Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.
Clinical takeaway. Clinical role: syngo.via molecular-imaging workflows provide viewing, manipulation, quantification, analysis, and comparison of medical images from one or more modalities and time points, including PET or nuclear-medicine functional data and CT or MR anatomical data. The workflows support disease-management activities in oncology, cardiology, neurology, and organ function, and the images or results may aid radiotherapy treatment planning. The submission also describes Scenium neurology review and syngo MBF quantitative myocardial-blood-flow review for supported PET studies.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports only non-clinical testing: risk analyses in compliance with ISO 14971, cybersecurity information, and software verification and validation confirming functions work as designed, performance requirements and specifications were met and hazard mitigations were implemented, with all testing meeting predetermined acceptance values; it lists recognized standards including IEC 62304 and NEMA PS 3.1 – 3.20. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
syngo.via molecular-imaging workflows provide viewing, manipulation, quantification, analysis, and comparison of medical images from one or more modalities and time points, including PET or nuclear-medicine functional data and CT or MR anatomical data. The workflows support disease-management activities in oncology, cardiology, neurology, and organ function, and the images or results may aid radiotherapy treatment planning. The submission also describes Scenium neurology review and syngo MBF quantitative myocardial-blood-flow review for supported PET studies.
The exact FDA document reports only non-clinical testing: risk analyses in compliance with ISO 14971, cybersecurity information, and software verification and validation confirming functions work as designed, performance requirements and specifications were met and hazard mitigations were implemented, with all testing meeting predetermined acceptance values; it lists recognized standards including IEC 62304 and NEMA PS 3.1 – 3.20. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Risk Management has been ensured via risk analyses in compliance with ISO 14971 to identify and provide mitigation to potential hazards" … "Cybersecurity information in accordance with FDA Guidance documents issued October 2, 2014 has been provided.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports only non-clinical testing: risk analyses in compliance with ISO 14971, cybersecurity information, and software verification and validation confirming functions work as designed, performance requirements and specifications were met and hazard mitigations were implemented, with all testing meeting predetermined acceptance values; it lists recognized standards including IEC 62304 and NEMA PS 3.1 – 3.20. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Risk Management has been ensured via risk analyses in compliance with ISO 14971 to identify and provide mitigation to potential hazards" … "Cybersecurity information in accordance with FDA Guidance documents issued October 2, 2014 has been provided.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K201195 FDA decision evidence package for syngo.via MI Workflows, syngo MBF
DesignFDA decision evidence and product verification described in the exact submission or PMA decision record.
PopulationWhole-body, cardiac, neurologic, oncologic, organ-function, and radiotherapy-planning anatomy represented in PET, nuclear-medicine, CT, and MR studies
Scopeexact submission
Tested versionsyngo.via MI Workflows, syngo MBF configuration described in K201195
IndependenceSponsor or vendor study
K201195
FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation unless the exact source expressly establishes that distinction; local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K201195 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported PET, SPECT, nuclear-medicine, CT, MR, tracer, physiologic-signal, and study inputs described in the labeling.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes the software as installed on the Siemens syngo.via platform and using supported molecular-imaging workflows; verify the installed release, DICOM routing, identity matching, archive, and local interface behavior.
Scope: Exact FDA submission. This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Processed, fused, quantitative, comparative, and report-ready molecular-imaging views for professional review.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Processed, fused, quantitative, comparative, and report-ready molecular-imaging views for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the software as installed on the Siemens syngo.via platform and using supported molecular-imaging workflows; verify the installed release, DICOM routing, identity matching, archive, and local interface behavior.
Exact FDA submission
Checked 2026-09-04
This is a partial interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Siemens Healthineers' corporate cybersecurity page states a Secure Development Lifecycle addressing pre-market and post-market phases for products under development and a range of existing offerings; a Cybersecurity Management Service maintaining a product security inventory (over 1,000 product versions and over 21,000 monitored software components) with security whitepapers, SBOMs and vulnerability assessments available to customers via teamplay Fleet; incident and vulnerability management channels; and that Siemens Healthineers AG maintains an independent certification of its global Cybersecurity Management System to ISO/IEC 27001:2022 extended by ISO/IEC 27701:2019, with the certificate referenced to the SGS directory. Vendor statement; no certificate or report was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: Siemens Healthineers' own corporate-info page names Siemens Medical Solutions USA, Inc. (Malvern, PA), and its 2024 governance press release states Siemens Healthcare GmbH's business was transferred to Siemens Healthineers AG. Corporate program statement; exact-release scope is not established.
Only qualified radiologists, nuclear-medicine physicians, and trained imaging professionals should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K201195 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.
Exact FDA submission
Checked 2026-09-04
This is buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.
exact submission · checked 2026-09-04
FDA-described topology does not establish current hosting contracts, security controls, uptime, or local qualification.
The exact FDA package describes the software as installed on the Siemens syngo.via platform and using supported molecular-imaging workflows; verify the installed release, DICOM routing, identity matching, archive, and local interface behavior.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Radiopharmaceutical, scan, reconstruction, quantitative, anatomy, and patient limits are exact-configuration dependent; clinical decisions remain with qualified clinicians.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
exact submission · checked 2026-09-04
No exact-product price or reimbursement determination was promoted.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission
No exact-product reimbursement determination was promoted in this timeboxed review. Verify payer, site-of-service, coding, coverage, and local payment assumptions independently.
Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission
The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.
Authorized purpose: uMI Panvivo and Panvivo S acquire and display PET and CT information for anatomical and functional imaging, radiopharmaceutical distribution, and the labeled oncology, cardiology, neurology, infection, inflammation, radiotherapy-planning, and interventional workflows.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body; brain; head and neck; heart; lung; breast; gastrointestinal; urinary; genital; and musculoskeletal anatomy
Authorized purpose: The Xeleris V Processing and Review System displays, processes, archives, prints, reports, and networks planar, SPECT, and PET nuclear-medicine data, with optional applications for DaTQUANT, lung analysis, brain analysis, coronary-flow reserve, prostate-cancer bone metastases, liver shunt and dose calculations, and monitoring of patient radiation doses from nuclear-medicine imaging data.
Modality
PET/SPECT/Nuclear Medicine
Anatomy
Whole body, lung, brain, liver, cardiac, coronary, and other anatomy represented in labeled nuclear-medicine studies
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.